Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.53 |
| ▸ | NEK7 | Q8TDX7 | 11/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30320498 | 0.89 | NEK7 (0.66) | FLT3NEK7 | |
| SCHEMBL24096483 | 0.89 | NEK7 (0.66) | FLT3NEK7 | |
| SCHEMBL25793723 | 0.82 | NEK7 (0.61) | NEK7 | |
| SCHEMBL25818044 | 0.81 | NEK7 (0.53) | FLT3NEK7 | |
| SCHEMBL25818041 | 0.80 | NEK7 (0.55) | FLT3NEK7 | |
| SCHEMBL25818033 | 0.80 | NEK7 (0.53) | FLT3NEK7 | |
| SCHEMBL25818004 | 0.80 | NEK7 (0.57) | FLT3NEK7 | |
| SCHEMBL25817974 | 0.79 | FLT3 (0.57) | FLT3NEK7 | |
| SCHEMBL25818071 | 0.79 | NEK7 (0.56) | NEK7 | |
| SCHEMBL30320596 | 0.79 | NEK7 (0.65) | FLT3NEK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | FLT3 886/4885NEK7 1/4885ROCK2 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.